Influence of obesity assessments on cardiometabolic risks in African and European American women

Insights

Cardiometabolic (CME) risks differ between African American women (AAW) and European American women (EAW) when evaluated by obesity. Systolic blood pressure and triglycerides were key risks for AAW, while SBP and glucose were significant for EAW.

Area of Science:

  • Cardiology
  • Public Health
  • Obesity Research

Background:

  • African American women (AAW) exhibit higher risks for cardiometabolic (CME) diseases and cardiovascular diseases (CVD) compared to European American women (EAW).
  • The specific impact of obesity on CME risk clustering and CVD disparities in AAW remains incompletely understood.

Purpose of the Study:

  • To develop a comprehensive CME index.
  • To investigate the relationship between obesity and CME risk index patterns stratified by race.

Main Methods:

  • A comparative research design involving 213 women (132 AAW, 81 EAW) from the Louisiana Delta.
  • Assessment of CME risk clustering using Body Mass Index (BMI), dual-energy X-ray absorptiometry % body fat, and waist circumference.
  • Measurement of fasting glucose, triglycerides (TG), high-density lipoprotein cholesterol (HDL-C), systolic blood pressure (SBP), and diastolic blood pressure (DBP) as key CME risks.

Main Results:

  • For AAW, SBP and TG were identified as significant CVD risks or near risks within obesity classifications.
  • For EAW, SBP and glucose trends indicated higher CME risk.
  • Stepwise regression revealed HDL-C and SBP/DBP as primary indicators of obesity's impact on CME risks in AAW, whereas SBP/DBP and glucose were key for EAW.

Conclusions:

  • Obesity-based CME risk profiles demonstrate distinct patterns between AAW and EAW.
  • Understanding these race-specific differences is crucial for targeted public health interventions and clinical management of cardiometabolic health.
Abstract

Related Concept Videos

Obesity01:24

Obesity

The Body Mass Index (BMI) is a numerical value derived from a person's weight and height, used to categorize individuals into weight ranges. It is calculated using the formula: weight in kilograms divided by height in meters squared. Obesity is a health condition characterized by excessive accumulation of adipose tissue that poses health risks, often diagnosed with a BMI ≥ 30. This excess fat storage occurs when surplus dietary calories are converted into triglycerides and stored in...
1.6K
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution01:25

Pharmacokinetics in Obese Patients: Drug Absorption and Distribution

Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
431
Drug Dosing: Obese Patients01:21

Drug Dosing: Obese Patients

In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
352
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion01:20

Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion

Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
310
Coronary Artery Disease I: Introduction01:30

Coronary Artery Disease I: Introduction

Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
1.7K
Assessment of the Cardiovascular System I: Subjective Data01:23

Assessment of the Cardiovascular System I: Subjective Data

A thorough health history and physical assessment are essential for identifying cardiovascular disease (CVD) symptoms and distinguishing them from other health issues.
Initial Enquiry
Ask the patient about their primary concern and thoroughly explore all reported symptoms.
Medical History
Investigate past illnesses affecting the cardiovascular system, such as angina, anemia, rheumatic fever, congenital heart disease, stroke, thrombophlebitis, dysrhythmias, varicosities
Inquire about symptoms...
1.1K